Novavax (NVAX) : 5 brokerage houses believe that Novavax (NVAX) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Novavax (NVAX). Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 6 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.33.
Novavax (NVAX) : Currently there are 6 street experts covering Novavax (NVAX) stock. The most bullish and bearish price target for the stock is $17 and $6 respectively for the short term. The average price target of all the analysts comes to $13.15. The estimated standard deviation from the target is $3.81.
For the current week, the company shares have a recommendation consensus of Buy. Novavax (NASDAQ:NVAX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.90 and $6.71 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.96. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.86, notching a gain of 0.44% for the day. The total traded volume was 5,675,190 . The stock had closed at $6.83 on the previous day.
In a related news, Phillips Barclay A, CFO of Novavax Inc, executed a transaction worth $1,810 on July 31, 2016. A total of 422 shares were purchased at an average price of $4.29. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).